Skip to main
  1. Stocks
  2. Anika Therapeutics
  3. Forecast
ANIK

Anika Therapeutics (ANIK) Stock Forecast & Price Target

Anika Therapeutics (ANIK) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anika Therapeutics is supported by a mature, profitable base business, with 9M26 gross margin at 64%, adjusted EBITDA meaningfully positive, and FY26 guidance raised on both revenue and margin. Its OEM channel represented 56% of 9M26 revenue and the commercial channel 44%, while no debt and $38.4M in cash provide balance-sheet flexibility to fund execution and buybacks. Upside is further driven by de-risked pipeline optionality: Cingal has three positive Ph3 trials, FDA said only a bioequivalence study remains before filing, and Hyalofast’s clarity lets investors focus on margin execution and the core HA franchise.

Bears say

Anika Therapeutics is facing a fundamental regulatory overhang as Hyalofast remains under FDA review, with the Phase III study missing its pre-specified co-primary endpoints and the company receiving a deficiency letter in 1Q26 tied to CMC and clinical data. The delayed approval timeline, now outside management’s control, also forced the company to exclude the previously implied $3 million of US Hyalofast revenue from its 2027 outlook, signaling limited near-term contribution from this program. Despite established overseas use in more than 35 countries and over 40,000 implantations, the uncertainty around US commercialization compounds an already concentrated revenue base that depends heavily on OEM and US-market products marketed exclusively by Johnson & Johnson MedTech.

Anika Therapeutics (ANIK) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Anika Therapeutics (ANIK) Analyst Forecast & Price Prediction

Get the latest Anika Therapeutics (ANIK) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Anika Therapeutics (ANIK)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anika Therapeutics (ANIK) Forecast

Analysts have given Anika Therapeutics (ANIK) a Buy based on their latest research and market trends.

According to 2 analysts, Anika Therapeutics (ANIK) has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anika Therapeutics (ANIK)


Anika Therapeutics (ANIK) Analyst Forecast & Price Prediction

Get the latest Anika Therapeutics (ANIK) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Anika Therapeutics (ANIK)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ANIK stock data and trends